Search

Displaying all 2 results
DrugBest match

Beremagene geperpavec

go.drugbank.com/drugs/DB17831
ApprovedInvestigational

Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1...

  1. Indication

    Wound

    go.drugbank.com/conditions/DBCOND0015509
    Drugs: Bacitracin · Benzoxonium · Beremagene geperpavec · Euflavine · Hyaluronic acid · Malic acid +6 more